Adamas Pharmaceuticals Inc.

6.65+0.1600+2.47%Vol 591 2031Y Perf -30.22%
Dec 13th, 2019 16:00
BID5.98 ASK6.66
Open6.47 Previous Close6.49
Pre-Market- After-Market6.66
 - -%  0.01 0.15%
Target Price
12.43 
Analyst Rating
Moderate Buy 2.30
Potential %
86.92 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     46.10
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap (M)185 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
35.79 
Earnings Date
7th Nov 2019

Today's Price Range

6.386.70

52W Range

3.3512.57

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
2.78%
1 Month
18.75%
3 Months
5.06%
6 Months
46.48%
1 Year
-30.22%
3 Years
-57.04%
5 Years
-52.40%
10 Years
-

TickerPriceChg.Chg.%
ADMS6.650.16002.47
AAPL275.153.69001.36
GOOG1 347.83-2.4400-0.18
MSFT154.531.29000.84
XOM69.23-1.1100-1.58
WFC53.79-0.5700-1.05
JNJ141.380.04000.03
FB194.11-2.6400-1.34
GE11.34-0.1000-0.87
JPM136.81-1.2100-0.88
Earnings HistoryEstimateReportedSurprise %
Q03 2019-0.90-0.99-10.00
Q02 2019-0.98-0.908.16
Q01 2019-1.13-1.084.42
Q04 2018-1.36-1.0622.06
Q03 2018-1.34-1.228.96
Q02 2018-1.41-1.2610.64
Q01 2018-1.38-1.352.17
Q04 2017-1.15-1.27-10.43
Earnings Per EndEstimateRevision %Trend
12/2019 QR-0.95-13.10Negative
12/2019 FY-3.91-4.55Negative
3/2020 QR-0.82-5.13Negative
12/2020 FY-2.47-3.35Negative
Next Report Date-
Estimated EPS Next Report-0.90
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume591 203
Shares Outstanding (K)27 858
Trades Count3 897
Dollar Volume4 042 149
Avg. Volume483 262
Avg. Weekly Volume418 282
Avg. Monthly Volume413 981
Avg. Quarterly Volume576 427
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (50.00 %)
5 (50.00 %)
5 (55.56 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (30.00 %)
3 (30.00 %)
3 (33.33 %)
Moderate Sell
1 (10.00 %)
1 (10.00 %)
0 (0.00 %)
Strong Sell
1 (10.00 %)
1 (10.00 %)
1 (11.11 %)
RatingModerate Buy
2.30
Moderate Buy
2.30
Moderate Buy
2.11

Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

CEO: Gregory T. Went

Teplephone: +1 510 450-3500

Address: 1900 Powell Street, Emeryville 94608, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

29%71%

Bearish Bullish

49%51%

News

Stocktwits